Navigation Links
Genedata Biologics for Biopharma R&D at Ninth Annual PEGS
Date:4/29/2013

Boston, MA (PRWEB) April 29, 2013

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that the latest Genedata software solutions will be featured at the Ninth Annual PEGS. Genedata Biologics™, an end-to-end solution for biologics R&D, will be showcased in the PEGS Phage and Yeast Display of Antibodies and Recombinant Proteins Session. The presentation will detail screening automation use cases from phage, yeast, and mRNA displays, as well as hybridomas and B-cells. Advanced workflow support for affinity maturation, the design and evaluation of engineered molecules, and subsequent automated expression, purification, and characterization of novel biologics candidates using Genedata Biologics will be presented. Genedata Biologics and Genedata Expressionist® for Mass Spectrometry will also be featured in poster sessions at PEGS, the foremost protein engineering summit (Seaport World Trade Center; April 29 – May 3).

Genedata Biologics and Genedata Expressionist for Biologics R&D
Genedata provides dedicated data management solutions tailored to address specific requirements in biologics R&D. Simplifying and streamlining laborious and manual lab processes such as cloning, the Genedata Biologics platform increases efficiency and throughput while reducing data handling errors to improve results quality. Automating and standardizing protein characterization processes, Genedata Expressionist for Mass Spectrometry , for example, identifies and quantifies post-translational modifications (PTMs) of biotherapeutics to assess developability.

PEGS presentation and poster sessions will examine how Genedata enables more flexible and ultra high-throughput workflows, and how classic process bottlenecks can be removed. Concrete use cases will include:

  • High-throughput engineering, cloning and expression of multi-specific next-generation antibodies
  • Expression system optimization and bioprocess development
  • Automation of mass spectrometry data analysis for biotherapeutics

“Through our close collaboration over the last five years with industry leaders combined with significant investments in resources, Genedata has been able to solve major data integration and analysis problems in biotherapeutics R&D,” noted Dr. Othmar Pfannes, CEO of Genedata. “Our investments have created a unique software solution for R&D organizations in need of scientific data integration and analysis. And, we are fully committed to continuing these investments and expanding the solution so that it becomes the platform of choice for biopharmaceutical R&D as well as biotherapeutics and biosimilars manufacturing.”

Editorial Note: On April 29 at 12:10pm EST, Genedata Biologics will be featured in the PEGS Phage and Yeast Display of Antibodies and Recombinant Proteins Session -- “Automated High-throughput Antibody Discovery and Optimization” -- by Dr. Christopher Smith. To schedule a briefing contact, jackie.thrasivoulos genedata.com.

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US. http://www.genedata.com.

Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Read the full story at http://www.prweb.com/releases/PEGS_Protein_Engineering/Bispecific_ADCs_Antibody/prweb10670569.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Genedata Screener to Present at 10th Annual Ion Channel Retreat
2. Genedata Expressionist® Established as Data Analysis Platform for Oncological Research
3. Genedata Screener for HCS Advances Phenotypic Screening
4. Genedata Screener Adopted for all Plate-based Screening by Major Pharmas
5. Genedata Biologics 3.0 Boosts Efficiency Through Standardization
6. Ono Pharmaceutical Selects Genedata Expressionist for Mass Spectrometry
7. Genedata Expressionist for Mass Spectrometry Showcased at 2013 Biotherapeutics Analytical Summit
8. Genedata Enables Research to Improve Personalized Treatment of Breast and Ovarian Cancer
9. Genedata Screener 11 with Compound Combination Screening and Collaboration in the Cloud Announced at Bio-IT World 2013
10. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
11. CMC Biologics Strengthens its Innovative Biomanufacturing Technology Portfolio in Continuous Perfusion Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... regenerative medicine, has announced a new agreement with Bankok,Thailand-based Global Stem Cells Network ... and phsyicians in 15 Latin American countries, including Mexico, Costa Rica, Dominican Republic, ...
(Date:2/10/2016)... -- The Maryland House of Delegates and House Speaker ... Maryland School of Medicine Dean E. Albert Reece ... System President and CEO Robert Chrencik , MBA, ... given to the public by the leader of the ... and Mr. Chrencik for their contributions to our statewide ...
(Date:2/10/2016)... 2016  IsoRay, Inc. (NYSE MKT: ISR), a medical ... radioisotope applications for the treatment of prostate, brain, lung, ... financial results for the second quarter and six months ... --> --> Revenue ... 2016, which ended December 31, 2015, a 12% increase ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... the International Society of Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter 21st Annual Vendor ... expecting to fill more than 100 tables for its annual event, which will ...
Breaking Biology Technology:
(Date:1/22/2016)... , January 22, 2016 ... the addition of the  "Global Behavioral ... offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ... "Global Behavioral Biometric Market 2016-2020"  report ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ...
(Date:1/20/2016)... Jan. 20, 2016 A market that just ... benefit from the explosion in genomics knowledge. Learn all ... Research. A range of dynamic trends are pushing market ... personalized medicine - pharmacogenomics - pathogen evolution - next ... markets - greater understanding of the role of genetic ...
(Date:1/18/2016)... Calif. , Jan. 18, 2016  Extenua ... software that simplifies the use and access of ... and go-to-market partnership with American Cyber.  ... brings extensive experience leading transformational C4ISR and Cyber ... and integrating the latest proven technology solutions," said ...
Breaking Biology News(10 mins):